Ocular Therapeutix is a company that has raised $14 million in Series D funding. This round of funding was led by Ascension Health Ventures with participation from Polaris Ventures, SV Life Sciences, and Versant Ventures. This round of funding will be used to support Ocular Therapeutix’s Phase II clinical trials of punctum plugs that are designed for managing dry eye, glaucoma, and allergies.
“Ocular Therapeutix is developing an exciting platform of products that promises to meet prevalent medical and surgical needs within a variety ophthalmic disorders,” stated Ascension Health Ventures Investment Director Tara Butler, M.D. “We are excited to be part of such promising technology.”